2013-vinci-annual-report
2013-vinci-annual-report
2013-vinci-annual-report
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Depreciation is calculated on a straight-line basis over an asset’s estimated useful life:<br />
Constructions<br />
10 to 40 years<br />
Other property, plant and equipment<br />
3 to 10 years<br />
The Company applies CNC Opinion 2004-06, issued by the Conseil National de la Comptabilité, on the definition, recognition and measurement<br />
of assets.<br />
3. Investments in subsidiaries and affiliates<br />
Investments in subsidiaries and affiliates are measured at their cost of acquisition. In accordance with CRC Regulation 2004-06, issued by<br />
the Comité de la Règlementation Comptable, on the definition and recognition of assets, VINCI includes the associated acquisition expenses<br />
in the cost of shares. If this cost is greater than the asset’s value in use, an impairment allowance is taken equal to the difference, as an<br />
exceptional item.<br />
Value in use is determined on the basis of the portion of the equity represented by the shares. This portion is adjusted if necessary to take<br />
account of the cash flow prospects for the companies in question.<br />
Capital gains or losses on disposal of shareholdings are recorded under exceptional income and expense.<br />
4. Trade receivables and related accounts<br />
Trade receivables are measured at their nominal value. An impairment allowance is recognised if there is a possibility of non-recovery of<br />
these receivables.<br />
5. Receivables and payables denominated in foreign currency<br />
Receivables and payables denominated in foreign currency are measured at the closing rate or at their hedged rate. Any gains or losses<br />
arising on this translation are recorded in the balance sheet as translation differences. Provisions are taken in respect of any unrealised losses<br />
unless specific rules are laid down in the accounting regulations.<br />
6. Marketable securities<br />
Marketable securities are recognised at their acquisition cost and an impairment loss is recorded whenever the cost is higher than the latest<br />
net realisable value at the period end.<br />
7. Financial instruments<br />
Loans (bonds, bank and intragroup borrowing) are recorded under liabilities at their nominal value. The associated issuance costs are recorded<br />
under deferred expenses, redemption premiums under assets, and issuance premiums under deferred income. These three items are amortised<br />
over the length of the loan.<br />
Loans and advances are recognised at nominal value. In the event of a risk of non-recovery, an impairment allowance is recognised.<br />
Forward financial instruments and derivative financial instruments are measured at the period end. A provision is recognised in the income<br />
statement for any unrealised losses only if the instruments are not designated as hedges.<br />
8. Treasury shares<br />
Treasury shares allocated to share purchase option and performance share plans are recognised under marketable securities.<br />
In accordance with CRC Regulation 2008-15, issued by the Comité de la Règlementation Comptable, a provision is taken as a financial expense<br />
during the period in which the beneficiaries’ rights vest, whenever an expense becomes probable.<br />
Treasury shares not allocated to plans are recorded under other non-current financial assets at their acquisition cost.<br />
An impairment allowance is recognised as a financial expense if the average stock market price of these shares during the last month of the<br />
period is lower than their unit cost. However, shares intended for cancellation are not written down.<br />
Whenever plans are hedged by call options, the premiums paid are recorded under marketable securities when the options hedge share<br />
purchase option plans or performance share plans, and under other non-current financial assets when these options hedge share subscription<br />
option plans.<br />
PARENT COMPANY FINANCIAL STATEMENTS 293